Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge
ConditionICU Acquired Weakness (ICUAW)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19+
SponsorAsan Medical Center
About this trial
This study aims to evaluate the feasibility, usability, and clinical effectiveness of a digital rehabilitation platform in adult patients discharged from the intensive care unit (ICU). Adult patients aged 19 years or older who stayed in the ICU for more than 48 hours and are capable of using a smartphone will be enrolled from two tertiary hospitals in South Korea.
Participants will receive individualized rehabilitation programs using a digital rehabilitation platform ("Tuntun Rehabilitation Assistant") based on their functional status. Rehabilitation will be conducted once daily for up to 30 minutes per session. Physical and cognitive function outcomes will be assessed at baseline, two weeks after intervention initiation, at hospital discharge, and during follow-up when applicable.
This prospective cohort study will investigate changes in physical function, mobility, cognitive status, and quality of life, as well as platform usage and safety-related events, to determine the clinical usefulness of digital rehabilitation for ICU survivors.
Eligibility criteria
Qualifiers
Age 19 years or older.
Admission to the intensive care unit (ICU) for more than 48 hours.
Hospitalization at Asan Medical Center or Seoul National University Bundang Hospital.
Discharge from the ICU at the time of enrollment.
Disqualifiers
Medical conditions that contraindicate participation in rehabilitation exercise, as determined by the attending physician.
Severe cognitive impairment or communication difficulties that interfere with understanding or following study instructions.
Unstable medical conditions requiring ongoing intensive medical treatment.
Inability to use a smartphone or digital platform independently.
Trial design
Treatments tested in this trial
- Digital Rehabilitation Group
Treatment groups
70 Participants
are divided into 1 treatment groupSponsors and collaborators
Asan Medical Center
Lead sponsor
Seoul National University Bundang Hospital
Collaborator
EverEx Inc.
Collaborator
Source ClinicalTrials.gov